Spots Global Cancer Trial Database for CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Official Title: A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Study ID: NCT03454451
Study Description
Brief Summary: This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Oncology, Tucson, Arizona, United States
City Of Hope, Duarte, California, United States
UC San Francisco, San Francisco, California, United States
Yale School of Medicine, New Haven, Connecticut, United States
University of Miami, Miami, Florida, United States
Northwestern University, Chicago, Illinois, United States
The University of Chicago, Chicago, Illinois, United States
The John Hopkins University, Baltimore, Maryland, United States
Dana Farber, Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
NY Hematology, Albany, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Carolina BioOncology Institute, Huntsville, North Carolina, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
UPMC Hillman, Pittsburgh, Pennsylvania, United States
Greenville, Greenville, South Carolina, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
Virginia Cancer, Fairfax, Virginia, United States
Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Lifehouse, Camperdown, New South Wales, Australia
St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
Westmead, Westmead, New South Wales, Australia
Royal Brisbane, Herston, Queensland, Australia
Monash Hospital, Clayton, Victoria, Australia
Contact Details
Name: S Mahabhashyam, MD
Affiliation: Corvus Pharmaceuticals
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
